What is Hemanext?
Hemanext is a Massachusetts-based medical technology company specializing in the development and manufacturing of a sophisticated medical device designed for the processing and storage of eligible red blood cells. This technology aims to enhance the efficiency and efficacy of blood management within healthcare systems. The company's focus on critical medical infrastructure positions it within a vital sector of the healthcare industry, addressing needs for improved blood product utilization and preservation.
How much funding has Hemanext raised?
Hemanext has raised a total of $130.9M across 10 funding rounds:
Private Equity
$12.3M
Private Equity
$2.7M
Debt
$2M
Debt
$350K
Series A
$15M
Series B
$18M
Multiple Rounds
$80.6M
Private Equity (2011): $12.3M, investors not publicly disclosed
Private Equity (2017): $2.7M, investors not publicly disclosed
Debt (2018): $2M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Series A (2021): $15M backed by Antaeus Wealth Advisors
Series B (2022): $18M, investors not publicly disclosed
Private Equity (2025): $20M, investors not publicly disclosed
Stock/Share Issuance (2025): $18.9M, investors not publicly disclosed
Private Equity (2025): $21.7M, investors not publicly disclosed
Private Equity (2025): $20M, investors not publicly disclosed
Key Investors in Hemanext
Antaeus Wealth Advisors
Antaeus Wealth Advisors is an integrated investment and financial planning firm based in Massachusetts, known for providing customized financial advice and guiding clients through market and life cycles. They focus on trust, integrity, and prosperity, putting client interests first.
What's next for Hemanext?
With the recent major strategic investment and the overall substantial enterprise-level funding, Hemanext is poised for significant expansion and technological advancement. This capital injection is expected to fuel further research and development, enhance manufacturing capabilities, and broaden market penetration for its red blood cell processing device. The company's strategic financing indicates a strong commitment from investors to support its mission of improving healthcare outcomes through advanced medical technology, likely leading to scaled operations and wider adoption of its solutions.
See full Hemanext company page
